ISPOR: The International Society for Pharmacoeconomics and Outcomes Research

Models Show Switch to Bevacizumab, Rituximab Biosimilars Yields Millions in Savings

May 25, 2020

Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from 2 studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.

Care Not in Line With Guidelines for HER2-Negative MBC Has Worse Outcomes in Elderly Women

May 23, 2020

More than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, and that was linked to higher mortality as well as higher Medicare costs.

What Innovations Can Improve Detection of Predictors, Severity in Parkinson Disease?

May 22, 2020

Presented at Virtual ISPOR 2020, researchers examined the efficacy of a machine learning approach in detecting predictors of Parkinson disease (PD), with an additional study testing the use of a statistical model to predict severity of PD.

Early Detection Programs May Help Offset Costs of COPD Exacerbations, Studies Find

May 21, 2020

Exacerbations of patients with chronic obstructive pulmonary disorder (COPD) can be costly if they are frequent, and early detection programs for COPD may help offset these costs, according to research from 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.

Studies Outline Asthma's Economic Toll

May 21, 2020

Although the total cost of asthma was more than $80 billion in 2013, the expansion of Medicaid in 2014 aided patients with asthma, according to 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.